Draft:David Roblin (physician)
David Roblin | |
|---|---|
 | |
| Known for | Pharma and biotech leadership |
| Awards | Academy of Medical Sciences member |
 | Review waiting, please be patient.
This may take 3 months or more, since drafts are reviewed in no specific order. There are 2,613 pending submissions waiting for review.
Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
Reviewer tools
|
David Roblin (physician) FRCP, FFPM, FMedSci (born 25 September 1966)[1] is a British physician and scientist specialising in drug discovery, pharmaceutical research, and translational medicine. He has held leadership roles in biotechnology and academia, contributing to the development of new therapeutics.
Early life and education
[edit]Roblin was born on 25 September 1966 in Neath, Wales. His parents were both secondary school teachers in Neath. He attended Cwmtawe Comprehensive School in Pontardawe.
He was educated at St George's Hospital Medical School, University of London, where he obtained a BSc in Biochemistry (First-Class Honours) in 1987 and an MB BS (Honours) in Medicine in 1991[1].
Career
[edit]Roblin began his medical career at St George's Hospital and St Bartholomew's Hospital in London. His involvement in clinical trials and translational research led to his transition into pharmaceutical research in 1995, when he took up a clinical position at Pfizer[1]. In 1997 he moved to Bayer as Head of Therapy Area for Anti-infectives, then moved back to Pfizer in 1999 as Senior Clinician[1].
During his time at Pfizer Global, Roblin held several senior leadership positions, including SVP, Head of Research, Site Director and Chief Medical Officer, European R&D. Over his 20 years in senior positions at Bayer at Pfizer he led teams up to 6,000 people. His experience crosses therapy areas from research and development to commercial phases. At Pfizer and Bayer he was instrumental in the successful development of 12 important medicines including Zithromax (azithromycin), Selzentry (maraviroc), ciprofloxacin and moxifloxacin[2].
Roblin has chaired the research director’s group of the European Federation of Pharmaceutical Industries and Associations (EFPIA), and was a co-founder of the Innovative Medicines Initiative, a public-private partnership with the European Commission[3]. He left Pfizer in early 2011, and has been Chief Medical Officer and a Non-Executive Director to a number of Biotechs[4].
Biotechnology and research leader
[edit]In 2014 Roblin became Chief Operating Officer and Director of Translation at the Francis Crick Institute[4]. In 2015, Roblin led the Crick’s first open science collaboration with GlaxoSmithKline (GSK), embedding industrial scientists within research teams to accelerate drug discovery[5]. He described this as: "A landmark agreement in open science... Together, we shall accelerate breakthroughs in understanding human health and disease"[5].
in June 2017 he stood down as as Chief Operating Officer and Director of Scientific Translation at the Crick to become Chief Operating Officer and President of Research & Development for Summit Therapeutics. He retained a role at the Crick, becoming a Senior Scientific Translation Fellow, advising the Crick Executive Committee and Board on commercial translation, and chair of the Crick's Translation Advisory Board[6].
In 2020 Roblin joined Juvenescence as Chief Operating Officer of the parent Corporation and CEO of the pharmaceutical division[7].
In 2022 Roblin became Chief Executive Officer of Relation Therapeutics, a pioneer of drug discovery using active-graph machine learning. He had been involved in Relation since its founding[8].
Academic and advisory roles
[edit]Roblin holds honorary professorships at St George's Hospital Medical School (2015–present) and Swansea University Medical School (2013–present). He has also served on committees and boards for the Academy of Medical Sciences, the Wellcome Trust, the Medical Research Council, the National Institute for Health Research and King's Health Partners Ventures.
Awards and honours
[edit]Roblin has been elected a Fellow of the Academy of Medical Sciences (FMedSci) (2017), a Fellow of the Royal College of Physicians (FRCP) (2004), and a Fellow of the Faculty of Pharmaceutical Medicine (FFPM) (2014), and a Global Fellow of Medicines Development of the International Federation of Associations of Pharmaceutical Physicians (2020)[1]. He is recognised as a Biotech leader[9][10].
Personal Life
[edit]Roblin is married to Dr. Sallyanne Roblin, and they have two sons and a daughter[1].
References
[edit]- ^ a b c d e f Who's Who 2024
- ^ "Professor David Roblin". Centauri Therapeutics. Retrieved 2025-05-27.
- ^ "Creabilis hires chief medical officer". Manufacturing Chemist. Retrieved 2025-05-27.
- ^ a b "Dr David Roblin joins the Francis Crick Institute as Chief Operating Officer and Director of Translation". Francis Crick Institute. 20 June 2014. Retrieved 2025-05-27.
- ^ a b Roblin, David (12 October 2015). "In Profile: Dr. David Roblin, Francis Crick Institute in London". European Pharmaceutical Manufacturer. Retrieved 2025-05-27.
- ^ "David Roblin, COO and Director of Scientific Translation, to join Summit". Francis Crick Institute. 18 Jan 2017. Retrieved 2025-05-27.
- ^ "High Calibre Additions to the Juvenescence Team". BioSpace. 21 May 2020. Retrieved 2025-05-27.
- ^ "Relation Therapeutics names David Roblin as CEO and Lindsay Edwards as CTO". UK Bioindustry Association. 9 June 2022. Retrieved 2025-05-27.
- ^ "David Roblin – BioLeader Interview". PIR International. October 2019. Retrieved 2025-05-27.
- ^ Luke Timmerman (31 March 2025). "David Roblin on Building a TechBio Company" (Podcast). The Long Run. Timmerman Report. Retrieved 2025-05-27.
External links
[edit]- Relation Therapeutics [1]